Vadadustat, which is used to treat anemia in patients with chronic kidney disease, has received domestic product approval. The Ministry of Food and Drug Safety (Minister Yu-Kyoung Oh) announced on the 13th that it had approved two doses (150 and 300mg) of Vadadustat from Mitsubishi Tanabe Pharma Korea Co., Ltd., a new drug for the treatment of anemia in patients with chronic kidney disease. Vadadustat is a treatment for anemia in adult patients with chronic kidney disease undergoing hemodialysis. Vadadustat is a treatment for anemia in adult patients with chronic kidney disease undergoing hemodialysis. The drug promotes red blood cell production by inhibiting proline hydroxylase, which breaks down hypoxia-inducible fa